Body mass index and weight gain as alternative or complementary hypothesis to explain olanzapine concentration-dose ratio accumulation.
Charpiat
Bruno
B
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000378:metabolism / Q000493:pharmacokinetics; D001569:Benzodiazepines / Q000009:adverse effects* / Q000378:metabolism / Q000493:pharmacokinetics; D001711:Biotransformation; D015992:Body Mass Index; D016903:Drug Monitoring; D006801:Humans; D000077152:Olanzapine; D015430:Weight Gain
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine